CoChat

SARS-CoV-2 immune evasion by variant B.1.427/B.1.429

Open access
McCallum, Matthew, Bassi, Jessica, Marco, Anna De, Chen, Alex, Walls, Alexandra C., Iulio, Julia Di, Tortorici, M. Alejandra, Navarro, Mary-Jane, Silacci-Fregni, Chiara, Saliba, Christian, Agostini, Maria, Pinto, Dora, Culap, Katja, Bianchi, Siro, Jaconi, Stefano, Cameroni, Elisabetta, Bowen, John E., Tilles, Sasha W, Pizzuto, Matteo Samuele, Guastalla, Sonja Bernasconi, Bona, Giovanni, Pellanda, Alessandra Franzetti, Garzoni, Christian, Van Voorhis, Wesley C., Rosen, Laura E., Snell, Gyorgy, Telenti, Amalio, Virgin, Herbert W., Piccoli, Luca, Corti, Davide, Veesler, David · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
PreprintCited by 127

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

SARS-CoV-2 entry is mediated by the spike (S) glycoprotein which contains the receptor-binding domain (RBD) and the N-terminal domain (NTD) as the two main targets of neutralizing antibodies (Abs). A novel variant of concern (VOC) named CAL.20C (B.1.427/B.1.429) was originally detected in California and is currently spreading throughout the US and 29 additional countries. It is unclear whether antibody responses to SARS-CoV-2 infection or to the prototypic Wuhan-1 isolate-based vaccines will be impacted by the three B.1.427/B.1.429 S mutations: S13I, W152C and L452R. Here, we assessed neutralizing Ab responses following natural infection or mRNA vaccination using pseudoviruses expressing the wildtype or the B.1.427/B.1.429 S protein. Plasma from vaccinated or convalescent individuals exhibited neutralizing titers, which were reduced 3-6 fold against the B.1.427/B.1.429 variant relative to wildtype pseudoviruses. The RBD L452R mutation reduced or abolished neutralizing activity of 14 out of 35 RBD-specific monoclonal antibodies (mAbs), including three clinical-stage mAbs. Furthermore, we observed a complete loss of B.1.427/B.1.429 neutralization for a panel of mAbs targeting the N-terminal domain due to a large structural rearrangement of the NTD antigenic supersite involving an S13I-mediated shift of the signal peptide cleavage site. These data warrant closer monitoring of signal peptide variants and their involvement in immune evasion and show that Abs directed to the NTD impose a selection pressure driving SARS-CoV-2 viral evolution through conventional and unconventional escape mechanisms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2021.03.31.437925

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Research works printed but not linked: 49

  1. 10.1126/science.abb2507 · DOI · Paper page
  2. 10.1038/nature16988 · DOI · Paper page
  3. 10.1016/bs.aivir.2019.08.002 · DOI · Paper page
  4. 10.1038/s41586-020-2012-7 · DOI · Paper page
  5. 10.1016/j.cell.2020.02.052 · DOI · Paper page
  6. W. T. Soh , Y. Liu , E. E. Nakayama , C. Ono , S. Torii , H. Nakagami , Y. Matsuura , T. Shioda , H. Arase , bioRxiv, in press.
  7. 2021, AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells, Cell Res., 31, 126, 10.1038/s41422-020-00460-y · DOI · Paper page
  8. 2020, Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody, Nature, 583, 290, 10.1038/s41586-020-2349-y · DOI · Paper page
  9. 2020, Veesler, Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology, Cell, 183, 1024, 10.1016/j.cell.2020.09.037 · DOI · Paper page
  10. 10.1126/science.abd0827 · DOI · Paper page
  11. 10.1126/science.abd0831 · DOI · Paper page
  12. 10.1016/j.cell.2021.03.029 · DOI · Paper page
  13. 10.1126/science.abc6952 · DOI · Paper page
  14. 10.1038/s41586-021-03324-6 · DOI · Paper page
  15. 10.1038/s41586-020-2456-9 · DOI · Paper page
  16. 10.1101/2020.09.30.318972 · DOI
  17. 10.1101/2020.12.29.424482 · DOI
  18. 2021, A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies, Nat. Commun., 12, 1715, 10.1038/s41467-021-21968-w · DOI · Paper page
  19. G. Song , W.-T. He , S. Callaghan , F. Anzanello , D. Huang , J. Ricketts , J. L. Torres , N. Beutler , L. Peng , S. Vargas , J. Cassell , M. Parren , L. Yang , C. Ignacio , D. M. Smith , J. E. Voss , D. Nemazee , A. B. Ward , T. Rogers , D. R. Burton , R. Andrabi , bioRxiv, in press.
  20. 10.1038/s41586-021-03402-9 · DOI · Paper page
  21. 2021, Others, Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings, January, 12, 2021
  22. 10.1038/s41586-021-03412-7 · DOI · Paper page
  23. 10.1038/s41586-021-03398-2 · DOI · Paper page
  24. 10.1101/2021.02.22.432189 · DOI
  25. 10.1101/2021.03.06.434193 · DOI · Paper page
  26. 10.1101/2021.03.09.434607 · DOI · Paper page
  27. 10.1101/2021.02.10.430696 · DOI
  28. 2021, Correlates of protection against SARS-CoV-2 in rhesus macaques, Nature, 590, 630, 10.1038/s41586-020-03041-6 · DOI · Paper page
  29. 10.1038/s41591-021-01285-x · DOI · Paper page
  30. 10.1016/j.cell.2021.03.013 · DOI · Paper page
  31. 10.1016/j.chom.2021.03.009 · DOI · Paper page
  32. 2020, The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity, Cell, 182, 1284, 10.1016/j.cell.2020.07.012 · DOI · Paper page
  33. 10.1101/2021.02.17.431683 · DOI
  34. 2020, Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding, Cell, 182, 1295, 10.1016/j.cell.2020.08.012 · DOI · Paper page
  35. 10.1016/j.cell.2021.01.037 · DOI · Paper page
  36. 10.1016/j.cell.2020.10.049 · DOI · Paper page
  37. 10.1056/NEJMc2031364 · DOI · Paper page
  38. E. Andreano , G. Piccini , D. Licastro , L. Casalino , N. V. Johnson , I. Paciello , S. D. Monego , E. Pantano , N. Manganaro , A. Manenti , R. Manna , E. Casa , I. Hyseni , L. Benincasa , E. Montomoli , R. E. Amaro , J. S. McLellan , R. Rappuoli , bioRxiv, in press.
  39. 2020, Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants, Elife, 9, e61312, 10.7554/eLife.61312 · DOI · Paper page
  40. 10.1101/2021.02.14.431043 · DOI · Paper page
  41. 10.1186/1471-2105-6-31 · DOI · Paper page
  42. 10.1093/molbev/mst010 · DOI · Paper page
  43. 10.1126/science.1205669 · DOI · Paper page
  44. 10.1073/pnas.94.26.14764 · DOI · Paper page
  45. 10.1128/JVI.02055-15 · DOI · Paper page
  46. 10.3390/v12050513 · DOI · Paper page
  47. 10.1101/2021.03.15.435528 · DOI
  48. 2020, Human immunodeficiency virus-1 viral load is elevated in individuals with reverse-transcriptase mutation M184V/I during virological failure of first-line antiretroviral therapy and is associated with compensatory mutation L74I, J. Infect. Dis., 222, 1108, 10.1093/infdis/jiz631 · DOI · Paper page
  49. 10.1038/s41467-020-15562-9 · DOI · Paper page

Cited by

See all 127

Metadata

Authors
McCallum, M., Bassi, J., Marco, A. D., Chen, A., Walls, A. C., Iulio, J. D., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., Agostini, M., Pinto, D., Culap, K., Bianchi, S., Jaconi, S., Cameroni, E., Bowen, J. E., Tilles, S. W., Pizzuto, M. S., Guastalla, S. B., Bona, G., Pellanda, A. F., Garzoni, C., Van Voorhis, W. C., Rosen, L. E., Snell, G., Telenti, A., Virgin, H. W., Piccoli, L., Corti, D., & Veesler, D.
Venue
bioRxiv (Cold Spring Harbor Laboratory)
Publisher
openRxiv
Published
2021-04-01
OpenAlex
W3144086685
Cited by
127
References
20
Type
posted content
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. https://app.cochat.ai/papers/10.1101/2021.03.31.437925
The paper
McCallum, M., Bassi, J., Marco, A. D., Chen, A., Walls, A. C., Iulio, J. D., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., Agostini, M., Pinto, D., Culap, K., Bianchi, S., Jaconi, S., Cameroni, E., Bowen, J. E., Tilles, S. W., Pizzuto, M. S., . . . Veesler, D. (2021). SARS-CoV-2 immune evasion by variant B.1.427/B.1.429. bioRxiv (Cold Spring Harbor Laboratory). https://doi.org/10.1101/2021.03.31.437925

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.